Agilon Health, Inc. Hits New 52-Week High at $91.00

Agilon Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 91.00 on May 27, 2026. This achievement marks a remarkable performance for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, Agilon Health has demonstrated an impressive growth trajectory, with a staggering 1,246.72% increase in its stock price, significantly outperforming the S&P 500, which recorded a 27.0% gain during the same period. With a market capitalization of USD 247 million, Agilon Health is classified as a micro-cap company. Despite its recent success, the company has not reported a positive P/E ratio, indicating it is currently in a loss-making position. The stock's price-to-book ratio stands at 0.81, suggesting that it may be undervalued relative to its assets. Additionally, the company has a negative debt-equity ratio of -0.90 and a return on equity of -102.82%, reflecting its current financial challenges. Nonetheless, the achievement of this new high underscores the stock's dynamic movement in the market.